PhRMA presses for 340B changes

In a blog post on Thursday, the Pharmaceutical Research and Manufacturers of America questioned whether or not the 340B program was meeting its intended purpose of improving access to medicines for vulnerable and uninsured Americans.

In the post, PhRMA EVP for Policy & Research Lori Reilly said 9% of 340B entities are disproportionate share (DSH) hospitals; however, they account for 81% of pharmaceutical sales volume, and in many cases provide minimal "charity care." If more than 8-11.75% of the population served by a hospital is covered by Medicaid, the entity qualifies as a DSH and can receive discounted drugs under 340B. ...